Miaomiao Wei, Liangliang Wang, Xin Liu, Yaping Deng, Sanhong Yang, Wenjie Pan, Xiaoshan Zhang, Guangchao Xu, Shune Xiao, Chengliang Deng
BACKGROUND: Secondary lymphedema is a chronic, disabling disease impacting over 50% of patients with cancer and lacking effective pharmacological treatment even for early- to mid-disease stages. Metformin reportedly exerts anti-inflammatory and anti-fibrotic effects and is safe, with minimal side effects; We investigated the role of metformin in lymphedema mouse models and examined underlying molecular mechanisms. METHODS: Male C57BL/6 mice (6-8-week-old; n=15/group) received metformin (300 mg/kg/day) by gavage on day 3 after lymphedema surgery; saline and sham groups were administered the same volume of saline...
February 22, 2024: Plastic and Reconstructive Surgery